3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
37
Prostatic Neoplasms
19
Multiple Myeloma
17
Neoplasm Metastasis
14
Osteoporosis
8
Neuroblastoma
6
Pain
5
Osteosarcoma
5
Neoplasms, Plasma Cell
5
Carcinoma, Non-Small-Cell Lung
5
Neoplasms
4
Lung Neoplasms
4
Carcinoma, Renal Cell
4
Sarcoma, Ewing
3
Bone Diseases, Metabolic
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Sarcoma
2
Rhabdomyosarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Osteonecrosis
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Kidney Neoplasms
2
Humoral Hypercalcemia Of Malignancy
2
Giant Cell Tumor of Bone
2
Carcinoma, Hepatocellular
2
Breast Neoplasms, Male
2
Adenocarcinoma
2
Interventions
Oxaliplatin
200
Capecitabine
116
S 1 (combination)
106
Fluorouracil
105
Docetaxel
100
Cisplatin
88
Leucovorin
75
Paclitaxel
71
Irinotecan
68
apatinib
43
sintilimab
42
Drug Therapy
42
Surgical Procedures, Operative
37
Hyperthermic Intraperitoneal Chemotherapy
34
pembrolizumab
32
Radiotherapy
31
Trastuzumab
30
Gastrectomy
23
Nivolumab
22
Epirubicin
22
Tegafur
21
Bevacizumab
21
XELOX
20
titanium silicide
19
camrelizumab
19
tislelizumab
17
Ramucirumab
17
Carboplatin
16
Neoadjuvant Therapy
15
Endoscopic Mucosal Resection
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Stomach Neoplasms
×
Zoledronic Acid
×
Clear all
NCT06759064
2025-11-19
IPIZA
Qilu Hospital of Shandong University
Phase 1/2
Recruiting
24 enrolled